{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:59:57Z","timestamp":1793897997044,"version":"4.8.0"},"reference-count":89,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Tuberculosis (TB) has been troubling humans for hundreds of years, is a highly infectious disease caused by <jats:italic>Mycobacterium tuberculosis<\/jats:italic> (Mtb) infection, Mtb can infect almost all organs of the body and is one of the deadly infectious diseases in the world. At present, the first-line treatment regimen has a long treatment cycle and is prone to multiple drug resistance. Anti-tuberculosis drugs and latent tuberculosis infection (LTBI) resistance are increasing year by year, and new targets and new bioactive compounds are urgently needed to treat this disease. This review focuses on the latest reported anti-TB drug targets and related compounds in recent years, reviews the current TB drug regimen and major defects, outlines the key drug targets developed to date in Mtb, and the current situation of newly discovered anti-TB resistant forms of drugs. To provide a reference for the research and development of new anti-TB drugs and bring new treatment strategies for TB patients.<\/jats:p>","DOI":"10.3389\/fmed.2024.1455715","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T15:35:35Z","timestamp":1729524935000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["The progress of Mycobacterium tuberculosis drug targets"],"prefix":"10.3389","volume":"11","author":[{"given":"Xin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoxiu","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuju","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.3390\/ijms24065202","article-title":"Tuberculosis: pathogenesis, current treatment regimens and new drug targets","volume":"24","author":"Alsayed","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/med.21602","article-title":"An overview of new antitubercular drugs, drug candidates, and their targets","volume":"40","author":"Bahuguna","year":"2020","journal-title":"Med Res Rev"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"833715","DOI":"10.3389\/fimmu.2022.833715","article-title":"The COVID-19\/tuberculosis Syndemic and potential antibody therapy for TB based on the lessons learnt from the pandemic","volume":"13","author":"Dass","year":"2022","journal-title":"Front Immunol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.3390\/pharmaceutics15102409","article-title":"Advances in diagnostics and drug discovery against resistant and latent tuberculosis infection","volume":"15","author":"Shleider Carnero Canales","year":"2023","journal-title":"Pharmaceutics"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41573-024-00897-5","article-title":"Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease","volume":"23","author":"Dartois","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1211388","DOI":"10.3389\/fimmu.2023.1211388","article-title":"Controlled human infection models in COVID-19 and tuberculosis: current progress and future challenges","volume":"14","author":"Morrison","year":"2023","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"210264","DOI":"10.1183\/16000617.0264-2021","article-title":"COVID-19 and tuberculosis: the double whammy of respiratory pathogens","volume":"31","author":"Shariq","year":"2022","journal-title":"Eur Respir Rev"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"20499361211016973","DOI":"10.1177\/20499361211016973","article-title":"The impact of COVID-19 on tuberculosis: challenges and opportunities","volume":"8","author":"Kant","year":"2021","journal-title":"Ther Adv Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3201\/eid2703.203456","article-title":"Parallels and mutual lessons in tuberculosis and COVID-19 transmission, prevention, and control","volume":"27","author":"Hopewell","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3238\/arztebl.2019.0729","article-title":"The diagnosis and treatment of tuberculosis","volume":"116","author":"Suarez","year":"2019","journal-title":"Dtsch Arztebl Int"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1002\/cpt.2261","article-title":"The treatment of tuberculosis","volume":"110","author":"Peloquin","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.drudis.2021.09.003","article-title":"Opportunities for overcoming tuberculosis: Emerging targets and their inhibitors","volume":"27","author":"Yang","year":"2022","journal-title":"Drug Discov Today"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-Pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/31159","article-title":"Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence","volume":"393","author":"Cole","year":"1998","journal-title":"Nature"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/17460441.2024.2319042","article-title":"In silico drug design strategies for discovering novel tuberculosis therapeutics","volume":"19","author":"Canales","year":"2024","journal-title":"Expert Opin Drug Discov"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"620","DOI":"10.2174\/0113894501306302240526160804","article-title":"Polypharmacology-driven discovery and Design of Highly Selective, dual and multitargeting inhibitors of Mycobacterium tuberculosis - a review","volume":"25","author":"Amandy","year":"2024","journal-title":"Curr Drug Targets"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1016\/j.apsb.2022.04.014","article-title":"Overcoming Mycobacterium tuberculosis through small molecule inhibitors to break down cell wall synthesis","volume":"12","author":"Kuang","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3390\/ijms241310482","article-title":"Target identification in anti-tuberculosis drug discovery","volume":"24","author":"Capela","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"102478","DOI":"10.1016\/j.mib.2024.102478","article-title":"Cell wall synthesizing complexes in Mycobacteriales","volume":"79","author":"Meyer","year":"2024","journal-title":"Curr Opin Microbiol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1056608","DOI":"10.3389\/fmicb.2022.1056608","article-title":"Anti-tuberculosis drug development via targeting the cell envelope of Mycobacterium tuberculosis","volume":"13","author":"Xu","year":"2022","journal-title":"Front Microbiol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"125022","DOI":"10.1016\/j.ijbiomac.2023.125022","article-title":"Protein targets in Mycobacterium tuberculosis and their inhibitors for therapeutic implications: a narrative review","volume":"243","author":"Sreelatha","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"103987","DOI":"10.1016\/j.drudis.2024.103987","article-title":"Recent advances in the development of DprE1 inhibitors using AI\/CADD approaches","volume":"29","author":"Chen","year":"2024","journal-title":"Drug Discov Today"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e202300099","DOI":"10.1002\/cmdc.202300099","article-title":"DprE1 inhibitors: enduring aspirations for future Antituberculosis drug discovery","volume":"18","author":"Yadav","year":"2023","journal-title":"ChemMedChem"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.drudis.2020.02.003","article-title":"The quest for the holy grail: new antitubercular chemical entities, targets and strategies","volume":"25","author":"Huszar","year":"2020","journal-title":"Drug Discov Today"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"8917","DOI":"10.1021\/acs.jmedchem.9b02075","article-title":"Molecule property analyses of active compounds for Mycobacterium tuberculosis","volume":"63","author":"Makarov","year":"2020","journal-title":"J Med Chem"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"611304","DOI":"10.3389\/fcimb.2021.611304","article-title":"Tuberculosis drug discovery: a decade of hit assessment for defined targets","volume":"11","author":"Oh","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"115539","DOI":"10.1016\/j.ejmech.2023.115539","article-title":"Quinolone analogues of benzothiazinone: synthesis, antitubercular structure-activity relationship and ADME profiling","volume":"258","author":"Dube","year":"2023","journal-title":"Eur J Med Chem"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1128\/AAC.00681-18","article-title":"Structure-based drug design and characterization of sulfonyl-Piperazine Benzothiazinone inhibitors of DprE1 from Mycobacterium tuberculosis","volume":"62","author":"Piton","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"40659","DOI":"10.1021\/acsomega.2c05307","article-title":"Recent advances of DprE1 inhibitors against Mycobacterium tuberculosis: computational analysis of physicochemical and ADMET properties","volume":"7","author":"Amado","year":"2022","journal-title":"ACS Omega"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"114946","DOI":"10.1016\/j.ejmech.2022.114946","article-title":"Pyrimidine derivatives with antitubercular activity","volume":"246","author":"Finger","year":"2023","journal-title":"Eur J Med Chem"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"107718","DOI":"10.1016\/j.jmgm.2020.107718","article-title":"Structure based pharmacophore modelling approach for the design of azaindole derivatives as DprE1 inhibitors for tuberculosis","volume":"101","author":"Kb","year":"2020","journal-title":"J Mol Graph Model"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/17460441.2023.2218082","article-title":"Recent advances in mycobacterial membrane protein large 3 inhibitor drug design for mycobacterial infections","volume":"18","author":"North","year":"2023","journal-title":"Expert Opin Drug Discov"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"6202","DOI":"10.3390\/ijms21176202","article-title":"MmpL3 inhibition: a new approach to treat nontuberculous mycobacterial infections","volume":"21","author":"Sethiya","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1002\/cmdc.202100359","article-title":"Mycobacterial membrane protein large 3 (MmpL3) inhibitors: a promising approach to combat tuberculosis","volume":"16","author":"Umare","year":"2021","journal-title":"ChemMedChem"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"5356","DOI":"10.1021\/acs.jcim.3c00616","article-title":"Inhibition mechanism of anti-TB drug SQ109: allosteric inhibition of TMM translocation of Mycobacterium Tuberculosis MmpL3 transporter","volume":"63","author":"Carbone","year":"2023","journal-title":"J Chem Inf Model"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1093\/jac\/dku553","article-title":"Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients","volume":"70","author":"Heinrich","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.3390\/biomedicines10112793","article-title":"MmpL3 inhibition as a promising approach to develop novel therapies against tuberculosis: a spotlight on SQ109, clinical studies, and patents literature","volume":"10","author":"Imran","year":"2022","journal-title":"Biomedicines"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00894-023-05814-y","article-title":"S288T mutation altering MmpL3 periplasmic domain channel and H-bond network: a novel dual drug resistance mechanism","volume":"30","author":"Ge","year":"2024","journal-title":"J Mol Model"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1574-6968.2007.00890.x","article-title":"An rmlA gene encoding d-glucose-1-phosphate thymidylyltransferase is essential for mycobacterial growth","volume":"275","author":"Qu","year":"2007","journal-title":"FEMS Microbiol Lett"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"643951","DOI":"10.3389\/fmicb.2021.643951","article-title":"Mycobacterium tuberculosis Thymidylyltransferase RmlA is negatively regulated by Ser\/Thr protein kinase PknB","volume":"12","author":"Qu","year":"2021","journal-title":"Front Microbiol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.pbiomolbio.2018.12.004","article-title":"A structural and functional perspective on the enzymes of Mycobacterium tuberculosis involved in the L-rhamnose biosynthesis pathway","volume":"145","author":"Dhaked","year":"2019","journal-title":"Prog Biophys Mol Biol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"105242","DOI":"10.1016\/j.bioorg.2021.105242","article-title":"Mycobacterium enoyl acyl carrier protein reductase (InhA): a key target for antitubercular drug discovery","volume":"115","author":"Prasad","year":"2021","journal-title":"Bioorg Chem"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"107250","DOI":"10.1016\/j.bioorg.2024.107250","article-title":"Unlocking InhA: novel approaches to inhibit Mycobacterium tuberculosis","volume":"146","author":"Wahan","year":"2024","journal-title":"Bioorg Chem"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1021\/acsinfecdis.2c00314","article-title":"Efficacy and mode of action of a direct inhibitor of Mycobacterium abscessus InhA","volume":"8","author":"Alcaraz","year":"2022","journal-title":"ACS Infect Dis"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1038\/s41467-017-02118-7","article-title":"Inhibition of D-ala:D-ala ligase through a phosphorylated form of the antibiotic D-cycloserine","volume":"8","author":"Batson","year":"2017","journal-title":"Nat Commun"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3390\/molecules23020324","article-title":"The biological properties and potential interacting proteins of d-Alanyl-d-alanine ligase a from Mycobacterium tuberculosis","volume":"23","author":"Yang","year":"2018","journal-title":"Molecules"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/cbdd.13899","article-title":"Discovery of novel antibacterial agents: recent developments in D-alanyl-D-alanine ligase inhibitors","volume":"98","author":"Qin","year":"2021","journal-title":"Chem Biol Drug Des"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.biopha.2018.04.021","article-title":"DNA gyrase inhibitors: Progress and synthesis of potent compounds as antibacterial agents","volume":"103","author":"Khan","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"128402","DOI":"10.1016\/j.ijbiomac.2023.128402","article-title":"Schematic-portfolio of potent anti-microbial scaffolds targeting DNA gyrase: unlocking ways to overcome resistance","volume":"256","author":"Pakeeraiah","year":"2024","journal-title":"Int J Biol Macromol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/bfgp\/elac029","article-title":"Targeting novel sites in DNA gyrase for development of anti-microbials","volume":"22","author":"Salman","year":"2023","journal-title":"Brief Funct Genomics"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1021\/acs.jcim.1c01390","article-title":"Identification of potent DNA gyrase inhibitors active against Mycobacterium tuberculosis","volume":"62","author":"Pakamwong","year":"2022","journal-title":"J Chem Inf Model"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.3390\/ijms24043313","article-title":"Investigation of multi-subunit Mycobacterium tuberculosis DNA-directed RNA polymerase and its rifampicin resistant mutants","volume":"24","author":"Monama","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"e0157320","DOI":"10.1128\/AAC.01573-20","article-title":"Disputed rpoB mutations in Mycobacterium tuberculosis and tuberculosis treatment outcomes","volume":"65","author":"Lin","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1128\/mBio.00812-17","article-title":"The new Xpert MTB\/RIF ultra: improving detection ofMycobacterium tuberculosisand resistance to rifampin in an assay suitable for point-of-care testing","volume":"8","author":"Chakravorty","year":"2017","journal-title":"MBio"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/JCM.00568-18","article-title":"FISHing Mycobacterium tuberculosis complex by use of a rpoB DNA probe bait","volume":"56","author":"Loukil","year":"2018","journal-title":"J Clin Microbiol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"e0276022","DOI":"10.1128\/spectrum.02760-22","article-title":"In vitro profiling of the synthetic RNA polymerase inhibitor MMV688845 against Mycobacterium abscessus","volume":"10","author":"Mann","year":"2022","journal-title":"Microbiol Spectr"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"112659","DOI":"10.1016\/j.ejmech.2020.112659","article-title":"Endeavors towards transformation of M. tuberculosis thymidylate kinase (MtbTMPK) inhibitors into potential antimycobacterial agents","volume":"206","author":"Jian","year":"2020","journal-title":"Eur J Med Chem"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2147\/DDDT.S228381","article-title":"In silico design and synthesis of Tetrahydropyrimidinones and Tetrahydropyrimidinethiones as potential thymidylate kinase inhibitors exerting anti-TB activity against Mycobacterium tuberculosis","volume":"14","author":"Venugopala","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2174\/1389450122666210122084332","article-title":"ATP synthase, an emerging target in TB drug discovery: review of SAR and clinical pharmacology of Diarylquinoline inhibitors","volume":"22","author":"Dhulap","year":"2021","journal-title":"Curr Drug Targets"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1021\/acs.jmedchem.6b01358","article-title":"Discovery of Imidazo[1,2-a]pyridine ethers and Squaramides as selective and potent inhibitors of mycobacterial adenosine triphosphate (ATP) synthesis","volume":"60","author":"Tantry","year":"2017","journal-title":"J Med Chem"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.bmc.2014.12.060","article-title":"Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis","volume":"23","author":"Singh","year":"2015","journal-title":"Bioorg Med Chem"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijantimicag.2012.09.012","article-title":"Biological evaluation of novel substituted chloroquinolines targeting mycobacterial ATP synthase","volume":"41","author":"Khan","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1039\/D3MD00587A","article-title":"Cytochrome bd oxidase: an emerging anti-tubercular drug target","volume":"15","author":"Saha","year":"2024","journal-title":"RSC Med Chem"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1080\/17460441.2023.2224553","article-title":"Novel targets and inhibitors of the Mycobacterium tuberculosis cytochrome bd oxidase to foster anti-tuberculosis drug discovery","volume":"18","author":"Harikishore","year":"2023","journal-title":"Expert Opin Drug Discov"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMc1913327","article-title":"Telacebec (Q203), a new antituberculosis agent","volume":"382","author":"de Jager","year":"2020","journal-title":"N Engl J Med"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1038\/s41598-018-20989-8","article-title":"The anti-mycobacterial activity of the cytochrome bcc inhibitor Q203 can be enhanced by small-molecule inhibition of cytochrome bd","volume":"8","author":"Lu","year":"2018","journal-title":"Sci Rep"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"7426","DOI":"10.1073\/pnas.1706139114","article-title":"Exploiting the synthetic lethality between terminal respiratory oxidases to kill Mycobacterium tuberculosis and clear host infection","volume":"114","author":"Kalia","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"116479","DOI":"10.1016\/j.ejmech.2024.116479","article-title":"New synergistic benzoquinone scaffolds as inhibitors of mycobacterial cytochrome bc1 complex to treat multi-drug resistant tuberculosis","volume":"272","author":"Chilamakuru","year":"2024","journal-title":"Eur J Med Chem"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2174\/1389450118666170125144557","article-title":"Cytochrome P450 structure, function and clinical significance: a review","volume":"19","author":"Manikandan","year":"2018","journal-title":"Curr Drug Targets"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"823","DOI":"10.2217\/fmb.12.56","article-title":"Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action","volume":"7","author":"Sacksteder","year":"2012","journal-title":"Future Microbiol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1021\/acsinfecdis.1c00259","article-title":"Structure, in vivo detection, and antibacterial activity of metabolites of SQ109, an anti-infective drug candidate","volume":"7","author":"Malwal","year":"2021","journal-title":"ACS Infect Dis"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1021\/jm070905o","article-title":"5\u2019-O-[(N-acyl)sulfamoyl]adenosines as antitubercular agents that inhibit MbtA: an adenylation enzyme required for siderophore biosynthesis of the mycobactins","volume":"50","author":"Qiao","year":"2007","journal-title":"J Med Chem"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1021\/acs.biochem.8b01153","article-title":"Kinetic analyses of the siderophore biosynthesis inhibitor Salicyl-AMS and analogues as MbtA inhibitors and antimycobacterial agents","volume":"58","author":"Bythrow","year":"2019","journal-title":"Biochemistry"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/mmi.13166","article-title":"The mycobacterial iron-dependent regulator IdeR induces ferritin (bfrB) by alleviating Lsr2 repression","volume":"98","author":"Kurthkoti","year":"2015","journal-title":"Mol Microbiol"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"e1004500","DOI":"10.1371\/journal.pcbi.1004500","article-title":"Mechanism of Iron-dependent repressor (IdeR) activation and DNA binding: a molecular dynamics and protein structure network study","volume":"11","author":"Ghosh","year":"2015","journal-title":"PLoS Comput Biol"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1021\/bi0609826","article-title":"Crystal structures, metal activation, and DNA-binding properties of two-domain IdeR from Mycobacterium tuberculosis","volume":"46","author":"Wisedchaisri","year":"2007","journal-title":"Biochemistry"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"103693","DOI":"10.1016\/j.drudis.2023.103693","article-title":"Tweaking host immune responses for novel therapeutic approaches against Mycobacterium tuberculosis","volume":"28","author":"Roy","year":"2023","journal-title":"Drug Discov Today"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"747799","DOI":"10.3389\/fimmu.2022.747799","article-title":"Macrophage: a cell with many faces and functions in tuberculosis","volume":"13","author":"Ahmad","year":"2022","journal-title":"Front Immunol"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.chom.2018.06.004","article-title":"Mechanisms of M. tuberculosis immune evasion as challenges to TB vaccine design","volume":"24","author":"Ernst","year":"2018","journal-title":"Cell Host Microbe"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"763591","DOI":"10.3389\/fcimb.2021.763591","article-title":"The research Progress in immunotherapy of tuberculosis","volume":"11","author":"Mi","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/mBio.03315-19","article-title":"Peptidoglycan hydrolases RipA and Ami1 are critical for replication and persistence of Mycobacterium tuberculosis in the host","volume":"11","author":"Healy","year":"2020","journal-title":"MBio"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"104412","DOI":"10.1016\/j.meegid.2020.104412","article-title":"Mycobacterium tuberculosis Rv3717 enhances the survival of Mycolicibacterium smegmatis by inhibiting host innate immune and caspase-dependent apoptosis","volume":"84","author":"Gong","year":"2020","journal-title":"Infect Genet Evol"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1080\/21505594.2020.1726561","article-title":"Distinct host-immune response toward species related intracellular mycobacterial killing: a transcriptomic study","volume":"11","author":"Madhvi","year":"2020","journal-title":"Virulence"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1080\/21505594.2021.1914448","article-title":"Deletion of N-acetylmuramyl-L-alanine amidases alters the host immune response to Mycobacterium tuberculosis infection","volume":"12","author":"Kieswetter","year":"2021","journal-title":"Virulence"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"e00812","DOI":"10.1128\/mBio.00812-17","article-title":"The New Xpert MTB\/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing","volume":"8","author":"Persing","year":"2017","journal-title":"mBio."},{"key":"ref86","doi-asserted-by":"publisher","first-page":"106312","DOI":"10.1016\/j.bioorg.2022.106312","article-title":"New tetrahydropyrimidine-1,2,3-triazole clubbed compounds: Antitubercular activity and Thymidine Monophosphate Kinase (TMPKmt) inhibition","volume":"131","author":"El-Shoukrofy","year":"2023","journal-title":"Bioorg Chem."},{"key":"ref85","doi-asserted-by":"publisher","first-page":"7683","DOI":"10.3390\/ijms21207683","article-title":"Hydroxylation of Antitubercular Drug Candidate, SQ109, by Mycobacterial Cytochrome P450","volume":"21","author":"Bukhdruker","year":"2020","journal-title":"Int J Mol Sci."},{"key":"ref87","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41541-024-00847-7","article-title":"BCG-booster vaccination with HSP90-ESAT-6-HspX-RipA multivalent subunit vaccine confers durable protection against hypervirulent Mtb in mice","volume":"9","author":"Kwon","year":"2024","journal-title":"NPJ Vaccines."},{"key":"ref89","doi-asserted-by":"publisher","first-page":"722","DOI":"10.22038\/IJBMS.2017.8859","article-title":"Design of peptides interfering with iron-dependent regulator (IdeR) and evaluation of Mycobacterium tuberculosis growth inhibition","volume":"20","author":"Salimizand","year":"2017","journal-title":"Iran J Basic Med Sci."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1455715\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T15:35:40Z","timestamp":1729524940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1455715\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":89,"alternative-id":["10.3389\/fmed.2024.1455715"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1455715","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]},"article-number":"1455715"}}